Individualization of treatment in non-small cell lung cancer

Nico van Zandwijk

Address: Bernie Banton Centre, University of Sydney, Hospital Road, Concord, 2139 NSW, Australia
Email: zwk@med.usyd.edu.au

F1000 Medicine Reports 2009, 1:24 (doi: 10.3410/M1-24)

Abstract

Two recently reported randomized studies discussed below are paving the way for personalized treatment approaches for patients with non-small cell lung cancer (NSCLC). Both studies show that accurate subclassification of NSCLC will become necessary to prescribe chemotherapy doublets and epidermal growth factor receptor tyrosine kinase inhibitors. It is expected that the practice of the last 30 years of lumping all NSCLC subtypes together will soon come to an end.

Introduction and context

Lung cancer is the leading cause of cancer death in the world and progress in the treatment of the different diseases under this heading has been modest in the last 25 years. The two most important reasons for the lack of progress are the fact that the majority of patients with lung cancer present with advanced (metastatic) disease and that responses to systemic therapy most frequently are partial and of relatively short duration. About 85% of all patients with lung cancer have 'non-small cell' histology, and international guidelines indicate that four cycles of so-called platinum doublet chemotherapy are standard. These guidelines do not address histology or which platinum doublet.

Recent advances

A recent study has shown that pemetrexed/cisplatin was superior to gemcitabine/cisplatin in two subgroups of patients with non-small cell lung cancer (NSCLC): adenocarcinoma and large cell carcinoma. The gemcitabine/cisplatin combination performed better in patients with squamous cell carcinoma [1]. This important observation (that is, the increased sensitivity to specific chemotherapeutic agents in subgroups of patients with NSCLC) has been confirmed recently by others [2,3]. The main target of pemetrexed is thymidylate synthase (TS). In NSCLC patients who underwent surgical resection, TS is expressed at a higher level in squamous cell carcinoma than in adenocarcinoma and this may well explain the better result of pemetrexed in adenocarcinoma.

These recent study results show that the oncological community now has the opportunity to leave the current practice of lumping different histologies together and to prescribe cytotoxic drugs on clinicopathological parameters. The art of selecting systemic therapy for NSCLC lies not only in knowing which drugs to use but also in the selection of subgroups of patients who are most likely to benefit from the treatment.

Another category of systemic agents for NSCLC is composed of oral tyrosine kinase inhibitors of the epidermal growth factor receptor (otherwise known as EGFR-TKIs). Two EGFR-TKIs, erlotinib and gefitinib, have been studied extensively in the last 6-7 years and were found to induce responses, improve symptoms, and in some instances to prolong survival in previously treated patients with NSCLC [4,5]. During early clinical development of the two drugs, it had become apparent that patients with adenocarcinoma and patients with little or no exposure to cigarette smoke had better responses to these two agents; moreover, Southeast Asian patients seemed to respond better [6].

In 2004, independent groups of investigators suggested that increased sensitivity to EGFR inhibitors was related to specific mutations in the EGFR domain [7,8].

Published: 24 March 2009
© 2009 Medicine Reports Ltd

for non-commercial purposes provided the original work is properly cited. You may not use this work for commercial purposes.

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits unrestricted use, distribution, and reproduction in any medium,
Prospective studies studying the efficacy of erlotinib and gefitinib in patients with EGFR mutations seemed to confirm this hypothesis [9], and very recently a randomized study revealed that gefitinib performs better than chemotherapy in a preselected group of Asian patients with adenocarcinoma (light or never smokers) with an EGFR mutation, whereas patients without a mutation had a more favourable result on chemotherapy [10].

**Implications for clinical practice**

Thus, there are multiple indications for the abandonment of the common practice of the last three decades of offering the same treatment to all patients with NSCLC. The studies cited above provide enough evidence to start using histology and mutation status as criteria for patient selection. The practical consequence of that will be a decrease in popularity of the fine-needle aspiration technique for diagnosis. Most likely, a cytological diagnosis will not be firm enough to serve as the basis for treatment advice in the near future. It is also worth mentioning that the determination of EGFR mutation status is quite laborious and needs an experienced hand. Therefore, it is generally felt that this selection criterion is not easily accessible to all oncology units. Solutions such as the introduction of specific diagnostic kits for EGFR mutations are currently being investigated.

The selection of subgroups of patients with NSCLC for therapy is becoming increasingly important. It is equally important to identify patients who are not likely to respond or live longer as a result of therapy. This is especially relevant for treatments related with significant toxicity or for which the cost-benefit ratio of the treatment is likely to be extremely high. An individualized treatment approach is becoming an important issue in NSCLC.

**Abbreviations**

EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; TKI, tyrosine kinase inhibitor; TS, thymidylate synthase.

**Competing interests**

The author declares that he has no competing interests.

**References**

1. Scaglioni GV, Parikh P, von Pawel J, Biemsa B, Vansteenkiste J, Manegold C, Servatowski P, Gatzemeier U, Digumarri R, Zukin M, Lee JS, Mellenenga A, Park K, Patil S, Rolski J, Golse T, de Marinis F, Simms L, Sugarman KP, Gandara D: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-51.

2. Peterson P, Park K, Fosella F, Gatzemeier U, John W, Wu Y, Peterson P, Adachi S, Zielinski CC: Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study. J Clin Oncol 2008, ASCO Annual Meeting Proceedings, 26(May 20 Suppl):Abstract 8011.

3. Ciuleanu TE, Brodowicz T, Belani CP, Kim J, Kraszowski M, Laack E, Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smid E, Averbuch S, Macleod A, Feyerelisova A, Dhillon RP, Baselga J: Multinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003, 21:2237-46.

4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Macleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Beijak A, Clark G, Santabarbara P, Seymour L, National Cancer Institute of Canada Clinical Trials Group: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:12-32.

5. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366:1527-37.